Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
Beta Bionics plans to link its iLet and mint insulin delivery platforms with Eversense 365 CGM, targeting a Q4 2026 commercial debut for iLet.
Rhea-AI Summary
Beta Bionics (BBNX) announced a partnership to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics’ Eversense 365 continuous glucose monitoring system. Commercial launch of the integrated iLet and Eversense 365 offering is expected in the fourth quarter of 2026, subject to completion of the integration. At launch, Beta Bionics expects iLet to support the broadest range of CGM manufacturer options among automated insulin delivery systems, aiming to maximize device choice for users. The companies have also committed to a future integration of the mint system with Eversense 365, combining adaptive insulin dosing with year-long glucose sensing.
Positive
- Integration with Eversense 365 adds another CGM option for iLet AID users
- Commercial launch of integrated iLet–Eversense 365 system targeted for Q4 2026
- Future mint–Eversense 365 integration commitment extends the platform’s potential user base
Negative
- None.
Key Figures
- Commercial launch timing
- Q4 2026
- Integrated iLet and Eversense 365 system
Historical Context
-
Senseonics and Beta Bionics formed an integration partnership for Eversense 365 and iLet
-
FDA cleared Mint patch pump and disclosed planned iLet and Mint commercialization
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
automated insulin delivery technical
continuous glucose monitoring medical
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system.
Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users.
The companies have also committed to the integration of mint and Eversense 365 in the future. This partnership underscores Beta Bionics’ and Senseonics’ shared commitment to bringing cutting-edge diabetes solutions to the market, while maximizing choice for people living with diabetes.
“This collaboration with Senseonics will expand our reach to a larger group of people with diabetes and empower them with maximum choice in the devices they rely on to manage their diabetes,” said Sean Saint, President & CEO of Beta Bionics. “We believe the combination of our fully adaptive AID platform with year-long glucose sensing offers a compelling and differentiated choice for people with diabetes in finding the system that is right for them.”
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding the integration of iLet and mint with Eversense 365, the timing or certainty of commercial launch of iLet and mint with Eversense 365 integration; and the implications and potential benefits of iLet and mint integration with Eversense 365. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, risks inherent in developing product candidates, the Company’s ability to obtain adequate financing to fund its product development and other expenses, the Company’s ability to manufacture and scale production of its products and manage its supply chain, the Company’s ability to obtain adequate reimbursement and payer coverage for its products, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What products are being integrated under the Beta Bionics and Senseonics partnership?
The partnership covers integration of the iLet Bionic Pancreas automated insulin delivery system with the Eversense 365 continuous glucose monitoring system, with a commitment to integrate the mint automated insulin delivery system with Eversense 365 in the future.
When is the integrated iLet and Eversense 365 system expected to be commercially available?
Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, assuming integration activities are completed as planned.
How does this integration affect choice of continuous glucose monitors for iLet users?
Beta Bionics expects that, at launch of the integrated system, iLet will support the most CGM manufacturer options of any automated insulin delivery system, which the company said is intended to maximize device choice for people using iLet.
What does Beta Bionics say about the potential benefits of combining its AID systems with Eversense 365?
Beta Bionics states that combining its fully adaptive automated insulin delivery platform with year-long glucose sensing from Eversense 365 offers a differentiated option for people with diabetes to find the system that best fits their needs.